The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated substantial gains, the expiration of its intellectual property protection opened the https://kathrynflsy348016.ourcodeblog.com/42206860/sildenafil-and-the-pharmaceutical-industry-a-risky-bet